Clinical Trial Update: Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of rituximab, chemotherapy, and yttrium-90 ibritumomab tiuxetan in patients with newly diagnosed diffuse large B-cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Centre Antoine Lacassagne | Conditions: Lymphoma | Phase 2 | Status: COMPLETED